HLA-DQB1-AS1 Promotes Cell Proliferation, Inhibits Apoptosis, and Binds with ZRANB2 Protein in Hepatocellular Carcinoma

Long, Jianwu; Liu, Longfei; Zhou, Xiaoyun; Lu, Xianzhou; Qin, Lei

doi:10.1155/2022/7130634

Cited by 4 publications

(3 citation statements)

References 28 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These TNF-related lncRNAs were involved in carcinogenesis, and inflammatory and immune responses (22)(23)(24)(25). A number of studies have also demonstrated that some of TNF-related lncRNAs are closely associated with cancer proliferation and survival (32)(33)(34)(35)(36)(37)(38). Thus, we analyzed the expression patterns and clinical significance of TNFrelated lncRNAs in LUAD.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, AC017100.1 was shown to be a protective factor for the prognosis of prostate cancer ( 35 ). HLA-DQB1-AS1 has been shown to interact with zinc finger RANBP2-type containing 2 (ZRANB2) protein to promote proliferation and inhibit apoptosis in hepatocellular carcinoma ( 36 ), suggest that higher expression of HLA-DQB1-AS1 might have a negative impact on survival in hepatocellular carcinoma, while it was demonstrated to be beneficial for the survival of patients with LUAD and melanoma ( 37 , 38 ). Therefore, the role of HLA-DQB1-AS1 in cancer was related to the type of cancers, and the mechanism needs to explore further.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Chen¹,

Wu²,

Wang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD) has become one of the most lethal cancers, for which the recurrence and survival rates remain unfavorable. The tumor necrosis factor (TNF) family is involved in tumorigenesis and tumor progression. Various long non-coding RNAs (lncRNAs) play important roles by mediating the TNF family in cancer. Therefore, this study aimed to construct a TNF-related lncRNA signature to predict prognosis and immunotherapy response in LUAD. Methods:The expression of TNF family members and their related lncRNAs in a total of 500 enrolled LUAD patients was collected from The Cancer Genome Atlas (TCGA). Univariate Cox and the least absolute shrinkage and selection operator (LASSO)-Cox analysis was used to construct a TNF family-related lncRNA prognostic signature. Kaplan-Meier (KM) survival analysis was used to evaluate survival status. The time-dependent area under the receiver operating characteristic (ROC) curve (AUC) values were used to assess the predictive value of the signature to 1-, 2-, and 3-year overall survival (OS). Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied to identify the signature-related biological pathways. Furthermore, tumor immune dysfunction and exclusion (TIDE) analysis was employed to evaluate immunotherapy response.Results: A total of 8 TNF-related lncRNAs significantly associated with OS of LUAD patients were used to construct a TNF family-related lncRNA prognostic signature. According to risk score, these patients were divided into high-and low-risk subgroups. The KM survival analysis indicated that patients in the high-risk group showed significantly less favorable OS than that of low-risk group. The AUC values in predicting 1-, 2-, and 3-year OS were 0.740, 0.738, and 0.758, respectively. Moreover, the GO and KEGG pathway analyses demonstrated that these lncRNAs were closely involved in immune-related signaling pathways. The further TIDE analysis indicated that high-risk patients had a lower TIDE score than that of low-risk patients, indicating that high-risk patients may be appropriate candidates for immunotherapy. Conclusions:For the first time, this study constructed and validated a prognostic predictive signature of LUAD patients based on TNF-related lncRNAs, and the signature showed good performance to predict immunotherapy response. Therefore, this signature may provide new strategies for individualized treatment of LUAD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Chen¹,

Wu²,

Wang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…In nucleotide analogs, naive patients with chronic HBV infection who have an AA genotype of the HLA-DQA1/DRB1 gene are more likely to develop HCC during entecavir treatment ( Kozuka et al, 2018 ). HLA-DQB1-AS1 can interact with ZRANB2 protein to promote cell proliferation and inhibit apoptosis in HCC ( Long et al, 2022 ). In addition, HLA-DQB1 polymorphisms increase the risk of HCC after hepatis C virus eradication ( Miki et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of immunogenic cell death associated genes expression, tumor microenvironment, and prognosis in hepatocellular carcinoma

Xiang

Liu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Immunogenic cell death (ICD) plays an important role in the development of cancers. This study attempted to explore the role of ICD in the prognosis of hepatocellular carcinoma (HCC).Methods: Gene expression and clinical data were downloaded from The Cancer Genome Alas and Gene Expression Omnibus dataset. The immune/stromal/Estimate scores of the tumor microenvironment (TME) were calculated by ESTIMATE and CIBERSORT algorithms. Kaplan-Meier analysis, functional enrichment analysis, least absolute shrinkage and selection operator (LASSO) analysis, and univariate and multivariate Cox regression analysis were used for prognostic gene screening and prognostic model construction. The correlation of immune cell infiltration and risk scores was analyzed as well. Molecular docking was used to explore the relevance of related genes to anti-cancer drugs.Results: Ten ICD associated differentially expressed genes in HCC were found, and all of them had good predictive ability for HCC. ICD gene high amount of expression group was associated with poor prognosis (p = 0.015). The TME, immune cell infiltration and gene expression were different between ICD high and low groups (all p < 0.05). Six ICD associated genes (BAX, CASP8, IFNB1, LY96, NT5E and PIK3CA) which could predict the survival status were identified and used to construct the prognostic model for HCC. A risk score was calculated and it could be used as an independent prognostic factor in HCC patients (p < 0.001). In addition, the risk score had a positive correlation with macrophage M0 (r = 0.33, p = 0.0086). Molecular docking indicated that sorafenib could bind strongly to the target protein, representing that sorafenib may exert anticancer effects through these six ICD associated genes.Conclusion: This study established a prognostic model including six ICD associated genes for HCC, which may deepen our understanding of ICD and guide therapy for HCC patients.

show abstract

Development and validation of ferroptosis-related lncRNA signature and immune-related gene signature for predicting the prognosis of cutaneous melanoma patients

et al. 2023

View full text Add to dashboard Cite

HLA-DQB1-AS1 Promotes Cell Proliferation, Inhibits Apoptosis, and Binds with ZRANB2 Protein in Hepatocellular Carcinoma

Cited by 4 publications

References 28 publications

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Comprehensive analysis of immunogenic cell death associated genes expression, tumor microenvironment, and prognosis in hepatocellular carcinoma

Development and validation of ferroptosis-related lncRNA signature and immune-related gene signature for predicting the prognosis of cutaneous melanoma patients

Contact Info

Product

Resources

About